Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality

T. E. Anijarv; A. T. Can; C. C. Gallay; G. A. Forsyth; M. Dutton; J. S. Mitchell; D. F. Hermens; J. Lagopoulos

doi:10.1093/ijnp/pyad006

Back

Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality

Journal article

Open access

Peer reviewed

Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality

T. E. Anijarv, A. T. Can, C. C. Gallay, G. A. Forsyth, M. Dutton, J. S. Mitchell, D. F. Hermens and J. Lagopoulos

International Journal of Neuropsychopharmacology, Vol.26(4), pp.259-267

2023

DOI: https://doi.org/10.1093/ijnp/pyad006

PMCID: PMC10109122

PMID: 36789509

Appears in Thompson Institute Research Collection

Files and links (2)

pdf

Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality11.34 MBDownload View

Published Version Open Access CC BY V4.0

url

https://doi.org/10.1093/ijnp/pyad006View

Published Version

Abstract

EEG

depression

ketamine

spectral analysis

suicidality

Suicide prevention

Ketamine

Neuroimaging

Thompson Institute Special Collection

UniSC Diversity Area - Disability and Inclusion

Background: Ketamine has considerable therapeutic potential in alleviating major depressive disorder and chronic suicidality. However, the clinical diagnosis of neuropsychiatric disorders requires more robust diagnostic criteria. Electroencephalography (EEG) has shown promise in classifying depressive and suicidal patients from healthy individuals. The present study aimed to identify changes in the spectral properties of EEG in patients with major depressive disorder and chronic suicidality after completing the 6-week Oral Ketamine Trial on Suicidality with follow-up occurring 4 weeks after final ketamine treatment and determine associations between EEG spectral output and clinical symptoms. Methods: Participants (n = 25) had 4-minute eyes closed resting state EEG recorded at frontal, temporal, centro-parietal, and occipital regions. Spectral analysis was performed with Welch's power spectrum density method, and the power of 4 distinct frequency bands was analyzed: theta, alpha, low-beta, and high-beta. Correlation analyses between changes in clinical symptoms and spectral power were conducted using Spearman's ranked correlation. Results: Between pre- and posttreatment, only centro-parietal alpha power decreased. Between posttreatment and follow-up, centro-parietal alpha increased again in addition to increases in temporal alpha, centro-parietal and temporal theta, and occipital low-beta and decreases in occipital theta and temporal low-beta. Additionally, the decrease of occipital theta positively correlated with clinical subscales for depression and stress. Conclusions: EEG spectral analysis revealed significant changes in theta, alpha, and low-beta frequency bands. Alpha band showed initial changes after treatment; however, this trended back toward baseline levels after the treatment cessation. In contrast, theta and low-beta showed significant power changes only after the treatment had ended.

Details

Title: Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality
Authors: T. E. Anijarv (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
A. T. Can (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
C. C. Gallay (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
G. A. Forsyth (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
M. Dutton (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
J. S. Mitchell (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
D. F. Hermens (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
J. Lagopoulos (Corresponding Author) - University of the Sunshine Coast, Queensland, Thompson Institute
Publication details: International Journal of Neuropsychopharmacology, Vol.26(4), pp.259-267
Publisher: Oxford University Press
Date published: 2023
DOI: 10.1093/ijnp/pyad006
ISSN: 1469-5111
PMID: 36789509; PMC10109122
Copyright note: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Grant note: Australian Commonwealth Government's Prioritizing Mental Health Initiative (2018-2019)
Organisation Unit: Thompson Institute; External
Language: English
Record Identifier: 99716033702621
Output Type: Journal article

Metrics

57 File views/ downloads

42 Record Views

15 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Web Of Science research areas: Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: SDGs from InCites